Biotech Assistant
Share useful research with your peers
in · Share on LinkedIn ↗
RESEARCH / LITERATURE

Research Literature

Find research, methods, and reviews across our scientific fields.

One collection · Original publication dates · Authors, journals & DOIs

All publications 147

Duplicate DOIs are merged. This is a selected collection, not an exhaustive bibliography.

Export this page · RIS ↓
Original research
European Journal of Drug Metabolism and Pharmacokinetics

Progesterone PopPK study combines machine-learning screening with conventional covariate modeling

Lu Wang; Jie Tang; Sufeng Zhou; Tangping Zhao; Ying Ding; Weiwei Gao; Xiaoyan Zhu; Feng Shao

A study in European Journal of Drug Metabolism and Pharmacokinetics modeled subcutaneous aqueous progesterone using single-dose crossover data from 50 healthy Chinese postmenopausal women. Machine-learning approaches screened potential covariates before conventional PopPK evaluation. Height and body-weight effects remained statistically identifiable but had limited clinical significance. Simulated repeated-dose exposure is model-derived, rather than an observed efficacy outcome in fertility patients.

Clinical Pharmacology & Model-Informed Development
Read guide →Original paper ↗

DOI: 10.1007/s13318-026-01048-4

Original research
Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

Yijia Li; Ting Yang; Xiyue Zhang; Rui Peng; Jifang Gong; Zihan Zhang; Bin Ma; Yu Hou; Yunxuan Liu; Kemeng Chen; Qidong Bai; Yian Fang; Changdi Cao; Jia Hao; Zhiwei Sun; Ziqiong Jiang; Mengying Dong; Chenlong Wei; Zhongtang Li; Qiang Zhang; Lin Shen; Xueqing Wang; Mi Deng; Changsong Qi; Lei Miao

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNPIn Vivo Cell Engineering & Gene EditingProtein degradation / PROTAC
Read guide →Original paper ↗

DOI: 10.1038/s41563-026-02769-2

Methods
Communications Chemistry

Direct-infusion method accelerates antibody peptide mapping in a peer-reviewed study

Austin Z. Salome; Marcel Morgenstern; Alexander S. Hebert; Craig D. Wenger; Pavel Sinitcyn; Benton J. Anderson; John S. Chlystek; Lia R. Serrano; Keaton L. Mertz; Ian J. Miller; Erik Miller-Galow; Malika P. Godamudunage; Michael Batt; Bhavin R. Patel; Gihoon Lee; Lloyd M. Smith; Scott T. Quarmby; Alayna M. George Thompson; Joomi Ahn; Harsha P. Gunawardena; Joshua J. Coon

A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.

Biologics Characterization & CMC Analytics
Read guide →Original paper ↗

DOI: 10.1038/s42004-026-02260-8

Reviews & perspectives
Frontiers in Pharmacology

Review assesses the safety limits and translational gaps of MCL-1 degradation strategies

Shuai Liu; Shan Jiang; Mengjiao Zhang; Weixiao Wang; Huiru Peng; Wei Yang

A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.

Protein degradation / PROTAC
Read guide →Original paper ↗

DOI: 10.3389/fphar.2026.2010618

Reviews & perspectives
Journal of Medicinal Chemistry

Perspective examines DCAF16 recruitment beyond CRBN and VHL

Xiaofan Ge; Hua Xiang; Guoshun Luo

A Journal of Medicinal Chemistry perspective examines DCAF16-recruiting degraders, including recruiting motifs, structure–activity relationships, and structural design principles. The original abstract discusses bifunctional and monovalent approaches and highlights movement of programs such as PLX-61639 and AMX-883 toward clinical evaluation. This is a medicinal chemistry synthesis, not a new comparative clinical trial or proof of superiority.

Protein degradation / PROTAC
Read guide →Original paper ↗

DOI: 10.1021/acs.jmedchem.6c02348

Original research
Nature Communications

Peptide–oligonucleotide nanohybrids deliver miRNA to injured bone in rats

Hao Xu; Yi Qin; Wenming Li; et al.

A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.

Oligonucleotide Therapeutics & DeliveryFormulation Development & Manufacturing
Read guide →Original paper ↗

DOI: 10.1038/s41467-026-79320-z

Original research
Nature

Cancer-selective frameshifting circuits show preclinical activity with systemic AAV9 delivery

Qiuyi Wang; Ao Chen; Yaoqi Liu; Xiaoxiao Yu; Hao Zhang; Yuqiang Yu; Pengyu Chen; Yue Zhang; Francis Ka-Ming Chan; Xiangwei Gao; Yuanhui Mao

A Nature study describes FAST gene circuits that exploit cancer-associated ribosomal frameshifting to conditionally express gasdermin D and trigger pyroptosis. According to the original abstract, systemic AAV9 delivery produced tumor regression and immune activation in mouse colorectal and pancreatic cancer models, with synergy alongside checkpoint blockade. These are cell and animal findings, not human clinical evidence.

In Vivo Cell Engineering & Gene Editing
Read guide →Original paper ↗

DOI: 10.1038/s41586-026-11200-4

Original research
Proceedings of the National Academy of Sciences

Bispecific protein drives dual receptor degradation in mouse eye-disease models

Jialun Zhang; Mingming Du; Lingying Ge; Yuheng Cao; Jiang Jiang; Xue Yin; Guangcun Chen; Qiangbin Wang

A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.

Protein degradation / PROTAC
Read guide →Original paper ↗

DOI: 10.1073/pnas.2613631123

Original research
Nature Nanotechnology

Rational design of lipid nanoparticles for brain delivery of RNA therapeutics

Meng Tian; Leiming Wang; Zhengwei Liu; Dinglingge Cao; Changyue Yu; Jeffrey L. Bennett; Eliza Bliss-Moreau; Chang Wang; Diana D. Kang; Yonger Xue; Yichen Zhong; Siyu Wang; Haoyuan Li; Xucheng Hou; Binbin Deng; Yizhou Dong

Researchers used the properties of more than 100 central nervous system drugs to design brain-directed ionizable lipids. HX1 nanoparticles delivered RNA and enabled gene editing in mouse brains, delivered reporter mRNA in a nonhuman primate, and reduced radiation-related brain injury in mice carrying Il10 mRNA. These are preclinical findings.

mRNA / LNP
Read guide →Original paper ↗

DOI: 10.1038/s41565-026-02326-7

Methods
Bioanalysis

Multiplex assay separates domain-specific ADA responses using a PEGylated Cas9 model

Jason Truesdale; Michael Mulvana; Stephen Lowes; Christopher Dishinger

A Bioanalysis paper describes development and prevalidation of a Luminex xMAP assay for simultaneous domain-specific anti-drug antibody detection. Using PEGylated Cas9 as a model, the authors report adjustable bead ratios and on-demand coupling to accommodate different minimum required dilutions. The original abstract supports assay feasibility, rather than universal validation across multidomain therapeutics or demonstrated clinical benefit.

Bioanalysis & Biomarkers
Read guide →Original paper ↗

DOI: 10.1080/17576180.2026.2753978

Reviews & perspectives
Frontiers in Chemistry

Review examines cocrystal performance and barriers to clinical translation

Muhammad Inam; Muhammad Hayat; Abuzar Osman

A Frontiers in Chemistry review examines pharmaceutical cocrystals as a way to modify dissolution and related biopharmaceutical properties without changing an API's chemical identity. The abstract distinguishes solubility-limited BCS II drugs from permeability-limited BCS IV drugs. It highlights gastrointestinal instability, manufacturing reproducibility, coformer selection, and limited pharmacokinetic evidence. Much of the reported performance evidence remains preclinical.

Pharmaceutical solid stateFormulation Development & Manufacturing
Read guide →Original paper ↗

DOI: 10.3389/fchem.2026.1965408

Reviews & perspectives
Bioanalysis

Review explains statistical pitfalls in anti-drug antibody assay cut points

Brijesh Kumar Verma

Based on the PubMed abstract, this review explains how sample selection, experimental balance, outlier handling, transformation, and statistical methods affect anti-drug antibody assay cut points. It addresses screening, confirmation, titers, drug tolerance, and reassessment using clinical baseline samples. This is a practical review of validation decisions, not a new clinical efficacy study.

Bioanalysis & Biomarkers
Read guide →Original paper ↗

DOI: 10.1080/17576180.2026.2758542

AI assistant ↗